Structure-Activity Relationship of Novel Kinase Inhibitors in Triple-Negative Breast Cancer: An X-ray Crystallographic Study
DOI:
https://doi.org/10.5281/zenodo.22644161Keywords:
kinase inhibitor, triple-negative breast cancer, X-ray crystallography, structure-activity relationship, structure-based drug designAbstract
Background: Triple-negative breast cancer (TNBC) lacks a validated hormonal or HER2-directed target, driving sustained interest
in the dysregulated kinase signaling networks, including PI3K/AKT/mTOR, cyclin-dependent kinases, mitotic kinases, focal
adhesion kinase, and receptor tyrosine kinases, that support its proliferation and metastasis. Objective: This narrative review
synthesizes the published medicinal chemistry, X-ray crystallographic, and translational literature on kinase inhibitors developed
for or evaluated against TNBC. Methods: We reviewed structure-activity relationship and structural biology studies of kinase
inhibitor chemotypes with reported relevance to TNBC, focusing on the principal kinase targets implicated in disease biology, the
X-ray co-crystal structures that have guided inhibitor optimization, substituent-driven potency and selectivity trends across
independent chemotypes, and the preclinical and clinical efficacy data available for these agents. Findings: X-ray crystallography
has directly informed inhibitor optimization across PI3Kalpha, CDK4-cyclin D, Aurora A, MPS1/TTK, and focal adhesion
kinase-directed programs, revealing induced-fit pockets, paralog-differentiating structural features, and covalent-modifiable
residues that translated into measurable gains in potency and selectivity. Halogenated hinge-binding substituents and dual-target
hybrid pharmacophores recur as productive structure-activity strategies across independently reported series, and most
crystallographically optimized leads demonstrate potent in vitro and in vivo activity in TNBC models, though clinical validation
remains largely confined to the AKT inhibitor capivasertib, which improved median progression-free survival from 4.2 to 5.9 months
and median overall survival from 12.6 to 19.1 months when added to first-line paclitaxel in the phase II PAKT trial. Conclusions:
Kinase-directed drug discovery for TNBC has matured into a structurally sophisticated field in which X-ray crystallography
routinely informs, rather than merely retrospectively explains, inhibitor design, but a substantial translational gap remains
between crystallographically validated preclinical candidates and clinically tested agents.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3):229-263, DOI:10.3322/caac.21834.
Mehlich D, Marusiak AA (2022) Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. Cancer Letters, 547(C):215775, DOI:10.1016/j.canlet.2022.215775.
Elwaie TA, Aref MMA, Ali HI (2026) Advances in the design and discovery of small-molecule tyrosine kinase inhibitors for breast cancer. RSC Advances, 16(34):31815-31855, DOI:10.1039/d6ra03011d.
Yang X, Zhang X, Huang M, Song K, Li X, Huang M, Meng L, Zhang J (2017) New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kα Complexed with a Potent Lead Compound. Scientific Reports, 7(1):14572, DOI:10.1038/s41598-017-15260-5.
Gharbi SI, Pelletier LA, Espada A, Gutierrez J, Gutierrez Sanfeliciano SM, Rauch CT, Ganado MP, Baquero C, Zapatero E, Zhang A, Benach J, Russell AM, Cano L, Gomez S, Broughton H, Pulliam N, Perez CM, Torres R, Debets MF, de Dios A, Puig O, Hilgers MT, Lallena MJ (2022) Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy. npj Breast Cancer, 8(1):126, DOI:10.1038/s41523-022-00494-y.
Innocenti P, Woodward HL, Solanki S, Naud S, Westwood IM, Cronin N, Hayes A, Roberts J, Henley AT, Baker R, Faisal A, Mak GWY, Box G, Valenti M, De Haven Brandon A, O'Fee L, Saville H, Schmitt J, Matijssen B, Burke R, van Montfort RLM, Raynaud FI, Eccles SA, Linardopoulos S, Blagg J, Hoelder S (2016) Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach. Journal of Medicinal Chemistry, 59(8):3671-3688, DOI:10.1021/acs.jmedchem.5b01811.
Zhang B, Zhu C, Chan ASC, Lu G (2023) Discovery of a first-in-class Aurora A covalent inhibitor for the treatment of triple negative breast cancer. European Journal of Medicinal Chemistry, 256(C):115457, DOI:10.1016/j.ejmech.2023.115457.
Long L, Zhang B, Peng W, Pan Y, Zhai H, Cheng B, Tu Z, Long Z, Zhou H, Liu Q, Lu G (2025) Optimization of Novel Quinazolines as Potent Aurora Kinase Inhibitors for Triple-Negative Breast Cancer Treatment. Journal of Medicinal Chemistry, 68(17):18197-18215, DOI:10.1021/acs.jmedchem.5c00107.
Jiang C, Chen K, Li D, Hu S, Jin Q (2026) Discovery and optimization of potent covalent threonine tyrosine kinase (TTK) inhibitors for the treatment of triple-negative breast cancer. European Journal of Medicinal Chemistry, 302:118271, DOI:10.1016/j.ejmech.2025.118271.
Li H, Sun L, Ling H, Chang Y, Ren S, Xin H, Wang H, Yin Q (2026) Identification of a pyrazolo[3,4-b]pyridine chemotype for dual focal adhesion kinase 1/2 (FAK1/2) targeting in triple-negative breast cancer. Bioorganic Chemistry, 179:110005, DOI:10.1016/j.bioorg.2026.110005.
Zhang D, Qiu Z, Lei H, Liu Y, Zhang L, Zhang Q (2026) Structural optimization and biological evaluation of 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine derivatives as potent FAK inhibitors for the treatment of triple negative breast cancers (TNBC). European Journal of Medicinal Chemistry, 302(P3):118370, DOI:10.1016/j.ejmech.2025.118370.
Lu D, Lyu W, Chi X, Li Q, Zhou Y, Lu B, Zhang X, Sun X, Wang Z, Xiu S, Yang T, Wang Z, Zheng R, Zhou J, Chen Y, Shi C, Song S, Zhang L, Liu Z (2025) Structure-Based Discovery of Quinazolin-2-amine Derivatives as Potent ROR1 Pseudokinase Inhibitors with In Vitro and In Vivo Efficacy against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 68(15):16138-16171, DOI:10.1021/acs.jmedchem.5c01080.
Khan A, Alshabrmi FM, Mohammad A, Shkoor M, Al-Zoubi RM, Ming LC, Agouni A (2026) An Integrative Computational Pipeline for CK2 Inhibitor Discovery in Triple-Negative Breast Cancer Using Virtual Screening, Molecular Dynamics, Machine Learning, and Density Functional Theory. Pharmaceuticals, 19(5):694, DOI:10.3390/ph19050694.
Halder D, Mukherjee S, Jeyaprakash RS (2025) Exploring target selectivity in designing and identifying PI3Kα inhibitors for triple negative breast cancer with fragment-based and bioisosteric replacement approach. Scientific Reports, 15(1):1890, DOI:10.1038/s41598-024-83030-1.
Salama EE, Youssef MF, Aboelmagd A, Boraei ATA, Nafie MS, Haukka M, Barakat A, Sarhan AAM (2023) Discovery of Potent Indolyl-Hydrazones as Kinase Inhibitors for Breast Cancer: Synthesis, X-ray Single-Crystal Analysis, and In Vitro and In Vivo Anti-Cancer Activity Evaluation. Pharmaceuticals, 16(12):1724, DOI:10.3390/ph16121724.
El Hamaky NFM, Hamdi A, Bayoumi WA, Elgazar AA, Nasr MNA (2026) Design, synthesis, and biological evaluation of quinazoline-benzohydrazide and quinazoline-benzothiazole hybrids uncovering a dual EGFR/VEGFR-2 inhibitor with pronounced cytotoxic activity against triple-negative breast Cancer. Bioorganic & Medicinal Chemistry, 133:118515, DOI:10.1016/j.bmc.2025.118515.
Lin S, Zhang X, Yu Z, Huang X, Xu J, Liu Y, Wu L (2022) Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers. Bioorganic & Medicinal Chemistry, 61:116739, DOI:10.1016/j.bmc.2022.116739.
Liu P, Liu Y, Zhang X, Chen R, Pan Y, Xu X, Huang W (2026) Discovery of Novel AURKA Inhibitors for Triple-Negative Breast Cancer (TNBC) Therapy via a Hybrid Virtual Screening Pipeline, Biological Evaluation and Molecular Dynamics Simulation. ACS Omega, 11(30):44712-44728, DOI:10.1021/acsomega.6c00415.
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, Dougherty B, Sarker SJ, Prendergast A, McLaughlin-Callan M, Burgess M, Lawrence C, Cartwright H, Mousa K, Turner NC (2020) Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38(5):423-433, DOI:10.1200/jco.19.00368.
